Short Term Virologic Efficacies of Telbivudine versus Entecavir against Hepatitis B-Related Hepatocellular Carcinoma
Table 2
Outcomes of antiviral therapy, as indicated by the mean reduction in serum DNA, HBV DNA suppression, undetectable HBV-DNA, and HBe seroconversion.
TLV (39)
ETV (47)
value
HBV DNA ( IU/mL)
4th week
3.32 ± 0.80
3.64 ± 1.06
0.228
12th week
2.94 ± 0.96
2.54 ± 1.02
0.253
24th week
2.24 ± 1.39
1.9 ± 0.82
0.348
HBV DNA suppression, (below 2000 IU/mL)
4th week
13/31 (41.9%)
15/32 (46.8%)
0.444
12th week
11/14 (78.6%)
22/27 (81.5%)
0.565
24th week
9/11 (81.8%)
28/32 (87.5%)
0.488
Nondetectable HBV DNA (below 20 IU/mL)
4th week
0/31
0/32
12th week
3/14 (21.4%)
5/27 (18.5%)
0.583
24th week
2/11 (18.1%)
12/32 (37.5%)
0.213
HBeAg seroconversion
4th week
2/21 (9.5%)
0/25
0.119
12th week
0/14
2/27 (7.4%)
0.248
24th week
0/11
0/32
Antiviral resistance
0
0
Hepatitis flare up
0
0
Variables are expressed as mean ± standard deviation (SD) or (%). Hepatitis flare up was defined as the elevation of alanine aminotransferase (ALT) level to more than 10 times the upper normal limit. TLV, telbivudine; ETV, entecavir; and HBeAg, hepatitis B e antigen.
